BioMarin Pharmaceutical Inc. (BMRN) is listed on NASDAQ in Pharmaceutical Stocks. It is $64.65, -0.98%, with a $12.5B market cap. RSI is 51.0, neutral. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 51.0 Neutral
Market Cap $12.5B
Volume 867.7K
Fundamentals — 10-Q Q2 2026
Revenue $1.8B
Net Income $150.3M
EPS $0.77
Gross Margin 77.3%
Operating Margin 13.7%
Net Margin 8.6%
Debt / Equity 0.7x
P/E Ratio 84.0x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Friberg Gregory R | EVP, Chief R&D Officer | Sell | 3,281 | $53.85 | $176,682 | 2026 May 7 |
| Guyer Charles Greg | EVP, Chief Technical Officer | Sell | 16,486 | $60.46 | $996,744 | 2026 Mar 11 |
| Friberg Gregory R | EVP, Chief R&D Officer | Sell | 6,326 | $60.38 | $381,937 | 2026 Feb 26 |
| Davis George Eric | EVP, Chief Legal Officer | Sell | 26,061 | $61.36 | $1.6M | 2026 Feb 26 |
| Burkhart Erin | GVP, Chief Accounting Officer | Sell | 1,786 | $59.31 | $105,928 | 2025 May 20 |
| Hubbard Cristin | EVP, Chief Commercial Officer | Sell | 273 | $64.92 | $17,723 | 2025 May 2 |
| Burkhart Erin | GVP, Chief Accounting Officer | Sell | 1,295 | $71.52 | $92,618 | 2025 Mar 19 |
| Guyer Charles Greg | EVP, Chief Technical Officer | Sell | 7,034 | $71.28 | $501,384 | 2025 Mar 6 |
| Burkhart Erin | GVP, Chief Accounting Officer | Sell | 1,344 | $68.38 | $91,903 | 2025 Feb 24 |
| Guyer Charles Greg | EVP, Chief Technical Officer | Sell | 5,278 | $66.37 | $350,301 | 2024 Nov 12 |
| Burkhart Erin | GVP, Chief Accounting Officer | Sell | 714 | $90.00 | $64,260 | 2024 Aug 13 |
| Mueller Brian | EVP, Chief Financial Officer | Sell | 5,000 | $75.19 | $375,950 | 2024 May 30 |
| Davis George Eric | EVP, Chief Legal Officer | Sell | 40,850 | $74.52 | $3.0M | 2024 May 28 |
| Bienaime Jean Jacques | Director | Sell | 40,000 | $81.38 | $3.3M | 2024 May 10 |
| Davis George Eric | EVP, Chief Legal Officer | Sell | 1,850 | $85.01 | $157,269 | 2024 May 2 |
| Ajer Jeffrey Robert | EVP, Chief Commercial Officer | Sell | 5,000 | $82.91 | $414,550 | 2024 May 2 |
| Bienaime Jean Jacques | Director | Sell | 40,000 | $91.13 | $3.6M | 2024 Apr 12 |
| Burkhart Erin | GVP, Chief Accounting Officer | Sell | 2,286 | $90.00 | $205,740 | 2024 Apr 10 |
| Davis George Eric | EVP, Chief Legal Officer | Sell | 24,602 | $88.34 | $2.2M | 2024 Mar 28 |
| Bienaime Jean Jacques | Director | Sell | 2,000 | $86.11 | $172,220 | 2024 Mar 6 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $72.17 | 37.1 | $10.0B |
| | $366.76 | 62.3 | $542.1B |
| | $76.62 | 35.2 | $15.0B |
| | $18.03 | 47.2 | $6.3B |
Take BMRN further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put BMRN in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when BioMarin Pharmaceutical Inc. next reports.
Set alerts on BMRN
Get notified when BioMarin Pharmaceutical Inc. hits your price targets or technical conditions are met.
Get Started Free